Viral vectors as potential HIV-1 vaccines

FEMS Microbiology Letters

Volumn 200, Issue 2, 2001, Pages 123-129

  Schnell, Matthias J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

HIV 1; Recombinant virus; Vaccine; Viral vector

Indexed keywords

ANTIGEN; VACCINE; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DNA VIRUS; FOOT AND MOUTH DISEASE; HEPATITIS A; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; RNA VIRUS; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS EXPRESSION; VIRUS RECOMBINANT;

AIDS VACCINES; DNA VIRUSES; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; RECOMBINATION, GENETIC; RNA VIRUSES; VIRUS REPLICATION;

EID: 0035948229     PISSN: 03781097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1097(01)00211-7     Document Type: Short Survey

References (39)

1. Progress in the development of an HIV-1 vaccine
2. Towards an HIV-1 vaccine: Lessons from studies in macaque models
3. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
4. Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine
5. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
6. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
7. Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain
8. Lessons for AIDS vaccine development from non-AIDS vaccines
9. Vaccine developments
10. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
11. AIDS vaccines show promise after years of frustration
12. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
13. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
14. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
15. SV40 as a vector for immunization against lentiviral envelope glycoproteins
16. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques
17. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees
18. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice
19. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
20. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
21. Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins
22. Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes
23. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes
24. A therapeutic HIV vaccine using coxsackie-HIV recombinants: A possible new strategy
25. Highly stable expression of a foreign gene from rabies virus vectors
26. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus
27. Recombinant rabies virus as potential live-viral vaccines for HIV-1
28. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates
29. Vaccination with VSV G protein exchange vactors expressing HIV Env and SIV Gag proteins protects rhesus macaques from challenge with highly pathogenic SHIV 89.6P
30. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract
31. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants
32. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies
33. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: Implications on HIV vaccine development
34. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection
35. Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein
36. Infectious enveloped RNA virus antigenic chimeras
37. Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines
38. The development of cowpea mosaic virus as a potential source of novel vaccines
39. Chimeric parvovirus B19 capsids for the presentation of foreign epitopes